Gilla Inc. (OTCQB:GLLA) and CannTrust Holdings Inc. (CSE:TRST) announced that they are working together to develop both private-label and branded cannabis vapor solutions. The products will be produced and distributed by CannTrust through its authorized distribution channels.
As quoted in the press release:
As previously announced on July 12, 2017, Gilla’s Toronto-based subsidiary, Gilla Enterprises Inc., has entered into a non-binding letter of intent (the “LOI”) with CannTrust, one of Canada’s premier licensed producers under the ACMPR program. The LOI calls for Gilla to collaborate with CannTrust to provide a cannabis vapor solution for distribution to their extensive client base in Canada. The proposed device and packaging will be submitted to Health Canada to obtain any necessary approvals post signing of a definitive agreement.
Under the terms of the LOI, Gilla and CannTrust would enter into a definitive agreement to provide the Licensed Products to CannTrust to produce and distribute in Canada through their authorized distribution channels. Gilla will work with CannTrust to develop full scale production-level standard operating procedures that will be used to manufacture the Licensed Products to comply with Health Canada’s ACMPR requirements; including device selection, packaging and other regulated criteria.
Graham Simmonds, chair and CEO of Gilla, commented:
We are pleased to announce CannTrust as our licensee partner in Canada. Canada is a very important market for Gilla and establishing a formal relationship with one of the fastest growing and most respected licensed producers in the country is an exceptional opportunity for us. We will continue to update the market on the future launch of these and future products in Canada.
Brad Rogers, president and COO of CannTrust, said:
CannTrust continues to broaden and innovate its product offering and working exclusively with Gilla in Canada allows us to secure a relationship with a global leader in the vape industry. Combining our cutting-edge cultivation, processing and extractions methods with Gilla’s extraction and product development expertise will significantly enhance our product offering and allow us to continue to build on our leading position in the Canadian medical cannabis market.